Teladoc Health, Inc.

NYSE:TDOC

Medical - Healthcare Information Services

Healthcare
$8.06 +2.57%

+$0.20 today

Market cap
$1.47B
Beta
2.14
P/E (TTM)
-8.1
EPS (TTM)
-$0.96
52W Low $4.40High $9.77

Volume 3.96M

Average 4.68M

TDOC Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Teladoc Health, Inc.NYSE: TDOC

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital declines year over year

Q1 FY2026 other working capital of $18.84M (cash outflow) fell 57.3% year over year, behind the -28.2% change in trailing-twelve-month other working capital. Sequentially, it rose 88.5% from the prior quarter. Over 3 fiscal years it compounded at +30.9% a year.

Context

  • Other working capital amounted to 1.4% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Other working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -57.3% toward the trailing-twelve-month pace of -28.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.84M+88.5% QoQ
Last fiscal yearDec 2025
-$35.9M+126.9% YoY
LTMMar 2026
-$10.66M-28.2% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.3%——
1 year+126.9%——
3-year CAGR+30.9%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(35.9M) USD
Year-over-year change
-126.9%

Other Working Capital vs competitors

How TDOC compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.2% is the 6th highest of 11, against a peer median of -12.7%.
  • Other working capital amounts to 0.4% of revenue for TDOC, versus a peer median of 1.8%.
TDOC Competitors
Other Working Capital for TDOC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EVOEvotec SELTM Mar 2026€44.49M EUR+205.7%—6.0%
PHRPhreesia, Inc.LTM Apr 2026$25.23M USD-810.6%—5.1%
SDGRSchrödinger, Inc.LTM Sep 2026$12.31M USD-110.2%—4.6%
TDOCTeladoc Health, Inc.LTM Mar 2026$10.66M USD-28.2%+30.9%0.4%
PHVSPharvaris N.V.LTM Sep 2026€8.94M EUR+39.2%-0.4%—
OMDAOmada HealthLTM Mar 2026$7.77M USD+213.6%+85.4%2.7%
OMCLOmnicell, Inc.LTM Mar 2026$7.25M USD-64.5%—0.6%
IMNMImmunome, Inc.LTM Sep 2026$5.5M USD+135.4%——
AZTAAzenta, Inc.LTM Sep 2026$4.99M USD-248.5%-55.6%0.8%
NVCRNovoCure LimitedLTM Mar 2026$4.4M USD+189.5%—0.7%
PGNYProgyny, Inc.LTM Jun 2026$313K USD-102.1%—0.0%
Peer median (excluding TDOC) —-12.7%-0.4%1.8%

Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(428.79M)(13.66B)(220.37M)(1B)(200.32M)
Depreciation & Amortization219.62M267.78M348.72M382.84M363.12M
Deferred Income Tax41.8M(7.84M)(1.9M)(1.15M)(41.41M)
Stock-Based Compensation302.59M217.85M201.55M145.95M80.41M
Change in Working Capital(43.99M)(48.39M)11.64M(36.32M)1.08M
Accounts Receivables(11.17M)(49.06M)(10.25M)(375K)25.13M
Inventory(19.49M)14.8M24.1M(9.75M)399K
Accounts Payables1.19M1.88M(4.19M)(10.37M)11.45M
Other Working Capital(14.51M)(16.01M)1.99M(15.83M)(35.9M)
Other Non-Cash Items102.76M13.42B10.38M803.59M91.48M
Operating Cash Flow193.99M189.29M350.02M293.68M294.36M
Capital Expenditures(8.53M)(16.48M)(156.35M)(10.79M)(8.89M)
Acquisitions (Net)(78.66M)000(81.9M)
Purchases of Investments00000
Sales of Investments60.9M2.51M00740K
Other Investing Activities8.72M2.51M1K(113.26M)(175.95M)
Investing Cash Flow(72.98M)(167.74M)(156.35M)(124.05M)(266M)
Debt Repayment(914K)(3.15M)00(550.63M)
Common Stock Issued42.59M12.39M11.13M8.31M3.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(730K)(2.74M)(278K)(2K)(4.11M)
Financing Cash Flow40.95M6.5M10.85M8.31M(551.65M)
Effect of Forex Changes(1.8M)(3.34M)965K(3.29M)6.06M
Net Change in Cash160.16M24.7M205.49M174.65M(517.24M)
Free Cash Flow185.46M172.81M193.67M282.89M285.46M

Teladoc Health, Inc.

NYSE:TDOC

Intrinsic Alpha fair value

Locked

Current Price

$8.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.